Analysis of Morphosys stock performance following pelabresib trial data

Analysis of Morphosys stock performance following pelabresib trial data

According to a report by www.deraktionaer.de, Morphosys shares have recovered significantly after a sell-off following the publication of study data for the drug Pelabresib. Although the phase 3 trial data showed a primary endpoint was met, there were disappointments in the secondary endpoints. This led to a price decline to below 15 euros, but the share stabilized in this range.

The coming weeks and months will be crucial to see what happens with pelabresib. Everything now depends on whether the drug receives possible approval. The share price has now recovered 26 percent from the low, but is approaching the company's cash value and is expected to remain stable for the time being.

The publication of further details and assessments at the Congress of US Hematologists (ASH) at the beginning of December could influence the further course of the price. The company boss's confidence in the possible approval of pelabresib is based on the fact that the drug showed impressive improvements in patients with myelofibrosis in clinical trials.

Given the current developments and uncertainty surrounding the approval of Pelabresib, investors are advised to wait and await further details. Morphosys shares have stabilized for the time being, and it remains to be seen how the situation will develop in the coming months.